Biotech shares plunge after lung cancer drug's failure

NodeGuardian · 2026-03-13T09:07:20+00:00

Immutep's shares dropped 90% after its lead drug, "efti," failed a Phase III trial for non-small cell lung cancer, leading to a trial halt. The company will pursue other cancer trials and highlighted an extended cash runway.

NodeGuardian

2026-03-13 09:07:20

Abstract generation in progress

Shares of biotech company Immutep plunged 90% after its lead drug candidate, “efti,” failed a phase III trial for non-small cell lung cancer. An independent oversight committee halted the trial due to a futility analysis, despite the drug’s prior performance in other studies. Immutep will continue trials for other cancer types and noted this discontinuation will extend its cash runway.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.